NCT06314529 Long-term Follow-up Study of BHC001 for TDT
| NCT ID | NCT06314529 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bioray Laboratories |
| Condition | Thalassemia, Beta |
| Study Type | OBSERVATIONAL |
| Enrollment | 6 participants |
| Start Date | 2022-12-14 |
| Primary Completion | 2036-12-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6 participants in total. It began in 2022-12-14 with a primary completion date of 2036-12-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
Eligibility Criteria
Inclusion Criteria: 1. Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s) 2. Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia. Exclusion Criteria: \- There are no exclusion criteria for this study
Contact & Investigator
Xiaochen Wang, PhD
STUDY CHAIR
Bioray Laboratories
Frequently Asked Questions
Who can join the NCT06314529 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 35 Years, studying Thalassemia, Beta. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06314529 currently recruiting?
Yes, NCT06314529 is actively recruiting participants. Contact the research team at xcwang@brlmed.com for enrollment information.
Where is the NCT06314529 trial being conducted?
This trial is being conducted at Nanning, China, Changsha, China.
Who is sponsoring the NCT06314529 clinical trial?
NCT06314529 is sponsored by Bioray Laboratories. The principal investigator is Xiaochen Wang, PhD at Bioray Laboratories. The trial plans to enroll 6 participants.